+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Opdivo

  • ID: 4462144
  • Drug Pipelines
  • 124 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T-cells. PD-1 and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation 28 and B7 family. The B7 family cell surface molecules and the cytotoxic T-lymphocyte antigen 4 family both regulate complex signaling pathways that affect T-cell activation, tolerance, and immunopathology. Blocking the interaction of the PD-1 receptor with its ligands may allow T cells to restore an anti-tumor immune response.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Opdivo : Non-small cell lung cancer (NSCLC)
Opdivo : Melanoma
Opdivo : Gastric cancer
Opdivo : Colorectal cancer (CRC)
Opdivo : Head and neck cancer
Opdivo : Hepatocellular carcinoma (HCC)
Opdivo : Bladder cancer
Opdivo : Glioblastoma (GBM)
Opdivo : Renal cell cancer (RCC)

LIST OF FIGURES
Figure 60: Tagrisso for non-small cell lung cancer – SWOT analysis
Figure 61: The authors drug assessment summary for Tagrisso in non-small cell lung cancer
Figure 62: The authors drug assessment summary for Tagrisso in non-small cell lung cancer
Figure 63: Tarceva for non-small cell lung cancer – SWOT analysis
Figure 64: The authors drug assessment summary for Tarceva in non-small cell lung cancer
Figure 6: The authors drug assessment summary of Opdivo for melanoma
Figure 65: Tarceva sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 65: Tecentriq for non-small cell lung cancer – SWOT analysis
Figure 66: The authors drug assessment summary for Tecentriq in non-small cell lung cancer
Figure 68: Tecentriq sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 69: Vargatef for non-small cell lung cancer – SWOT analysis
Figure 12: The authors drug assessment summary of Opdivo for colorectal cancer
Figure 70: The authors drug assessment summary for Vargatef in non-small cell lung cancer
Figure 71: The authors drug assessment summary for Vargatef in non-small cell lung cancer
Figure 72: Xalkori for non-small cell lung cancer – SWOT analysis
Figure 16: The authors drug assessment summary of Opdivo for SCCHN
Figure 73: The authors drug assessment summary for Xalkori in non-small cell lung cancer
Figure 74: The authors drug assessment summary for Xalkori in non-small cell lung cancer
Figure 76: Zykadia for non-small cell lung cancer – SWOT analysis
Figure 20: The authors drug assessment summary of Opdivo for hepatocellular carcinoma
Figure 76: The authors drug assessment summary for Zykadia in non-small cell lung cancer
Figure 22: Opdivo for urothelial bladder cancer – SWOT analysis
Figure 77: The authors drug assessment summary for Zykadia in non-small cell lung cancer
Figure 78: Zykadia sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 79: Capmatinib for non-small cell lung cancer – SWOT analysis
Figure 26: The authors drug assessment summary for Opdivo in glioblastoma
Figure 80: The authors drug assessment summary for capmatinib in non-small cell lung cancer
Figure 81: The authors drug assessment summary for capmatinib in non-small cell lung cancer
Figure 82: Capmatinib sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 83: Cemiplimab for non-small cell lung cancer – SWOT analysis

LIST OF TABLES
Table 1: Opdivo drug profile
Table 2: Opdivo pivotal trial data in non-small cell lung cancer
Table 3: Opdivo CheckMate-026 Phase III data in non-small cell lung cancer
Table 4: Opdivo ongoing late-phase clinical trials in non-small cell lung cancer
Table 83: Tagrisso pivotal trial data in non-small cell lung cancer
Table 6: Opdivo sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 7: Opdivo patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 8: Opdivo drug profile
Table 9: Opdivo pivotal trial data in melanoma
Table 10: Opdivo ongoing late-phase clinical trials in melanoma
Table 11: Opdivo sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 12: Opdivo patient numbers for melanoma across the US, Japan, and five major EU markets, by country, 2017–26
Table 13: Opdivo drug profile
Table 14: Opdivo pivotal trial data in gastric cancer
Table 15: Opdivo Phase III trials in gastric cancer
Table 16: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 17: Opdivo patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
Table 18: Opdivo drug profile
Table 19: Opdivo pivotal trial data in colorectal cancer
Table 20: Opdivo early-phase trials in colorectal cancer
Table 21: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 22: Patients treated with Opdivo across the US and five major EU markets, by country, 2016–25
Table 23: Opdivo drug profile
Figure 71: Vargatef sales for NSCLC across the five major EU markets, by country, 2017–26
Table 25: Opdivo ongoing late-phase trials in head and neck cancer
Table 26: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 27: Opdivo patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
Table 28: Opdivo drug profile
Table 29: Opdivo Phase III trial in HCC
Table 30: Opdivo Phase I/II data in HCC
Table 31: Opdivo pivotal trial data in urothelial bladder cancer
Table 32: Opdivo ongoing late-phase trials in urothelial bladder cancer
Table 33: Opdivo drug profile
Table 34: Opdivo Phase III data in glioblastoma
Table 35: Opdivo Phase III trials in glioblastoma
Table 36: Opdivo drug profile
Table 37: Opdivo ongoing Phase III clinical trial in renal cell cancer
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll